In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

Clinical Trials Search Results

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 55 for your search:
Drug:  pegylated liposomal doxorubicin hydrochloride
Find trials that include:  Any drugs shown
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Diagnostic, Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: LITE Randomized Pilot Study, NCT00531973

2.

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 19 and over
Sponsor: NCI
Protocol IDs: NCI-2014-00629, GOG-0281, U10CA027469, U10CA180868, NCT02101788

3.

Phase: Phase III
Type: Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: MITO-8, 2008-001755-22, NCT00657878

4.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: FEDEGYN 02 / 0410-CHIPOR, 2010-023035-42, NCT01376752

5.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ET-D-009-10, NCT01379989

6.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: ACTG A5263, 1U01AI068636, U01CA121947, NCT01435018

7.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: LTS12674, 2011-006246-33, U1111-1127-0888, NCT01593228

8.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: MITO-16 -MANGO-OV2b, 2012-004362-17, ENGOT-ov 17, NCT01802749

9.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AGO-OVAR 2.21 / ENGOT ov-18, NCT01837251

10.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR100654, DOXILOVC3001, NCT01840943

11.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CR100983, ET743OVC3006, 2012-004808-34, NCT01846611

12.

Phase: Phase III
Type: Treatment
Status: Active
Age: 14 to 60
Sponsor: Pharmaceutical / Industry
Protocol IDs: ChangzhouJP, NCT02070523

13.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 0711003269, NCT00785798

14.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LAPADO-Study, 2007-000924-42, NCT01172223

15.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MM08-141, NCT01177683

16.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 201102043, NCI-2011-00224, NCT01246063

17.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: PO-MM-PI-0049, PDD-2011, NCT01541332

18.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: APR-407, NCT02098343

19.

Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: MCC-17814, NCT02186834

20.

Phase: Phase II, Phase I
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: X16041, IISR-2013-M100118, NCT02206425

21.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CDR0000065903, UTHSC-MS-96205, NCI-V97-1356, NCT00003135

22.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: NCRR
Protocol IDs: NCRR-M01RR00030-0156, M01RR00030, NCT00006433

23.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: DO03-21-005, NCT00159094

24.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: Myocet 008 (L017), NCT00250874

25.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: LY-012006, NCT00333008
1    
New Search